Bortezomib inhibits expression of TGF-β1, IL-10, and CXCR4, resulting in decreased survival and migration of cutaneous T cell lymphoma cells.
about
Apoptosis Induction and Gene Expression Profile Alterations of Cutaneous T-Cell Lymphoma Cells following Their Exposure to Bortezomib and MethotrexateMolecular basis of targeted therapy in T/NK-cell lymphoma/leukemia: A comprehensive genomic and immunohistochemical analysis of a panel of 33 cell linesIKK inhibition increases bortezomib effectiveness in ovarian cancer.Dimethyl fumarate restores apoptosis sensitivity and inhibits tumor growth and metastasis in CTCL by targeting NF-κB.The mucin MUC1 modulates the tumor immunological microenvironment through engagement of the lectin Siglec-9.CCR10/CCL27 crosstalk contributes to failure of proteasome-inhibitors in multiple myeloma.Genetics of Cutaneous T Cell Lymphoma: From Bench to Bedside.Histone Deacetylase (HDAC) Inhibition Induces IκB Kinase (IKK)-dependent Interleukin-8/CXCL8 Expression in Ovarian Cancer Cells.DMF: a promising therapeutic option in CTCL.The proteasome inhibitor bortezomib attenuates renal fibrosis in mice via the suppression of TGF-β1.CRIg, a tissue-resident macrophage specific immune checkpoint molecule, promotes immunological tolerance in NOD mice, via a dual role in effector and regulatory T cells.Cutaneous localization in multiple myeloma in the context of bortezomib-based treatment: how do myeloma cells escape from the bone marrow to the skin?Mobilization of human immature hematopoietic progenitors through combinatory use of bortezomib and immunomodulatory drugs.Apelin inhibited epithelial-mesenchymal transition of podocytes in diabetic mice through downregulating immunoproteasome subunits β5iAn Observational Study from Long-Term AAV Re-administration in Two Hemophilia Dogs
P2860
Q36255777-33920E1C-0BDC-4BD1-81BE-191E4B71F974Q36372043-DA1D1857-72C9-4783-A9CD-2489129E1145Q36413454-0DB4A8CC-819F-462F-9DB3-6263A6425392Q37262461-918D0D8B-E58A-4017-97C4-9BBBFB94E8E7Q37600827-51D8D382-6F84-4417-9173-8A5B16903279Q37694678-B91491E6-169B-4EAE-896F-AC587658BFDBQ38855013-C306397B-EB76-475D-A73B-AB787E8467DAQ38975491-7DF15306-261F-482B-AE25-9D3AA4C02B92Q42361264-E51326C1-E4C4-4993-816B-CA0B7DD653D8Q42376166-761CA939-4F83-4F0E-A535-3BE2944274BBQ46406078-1318DC74-56DB-46CB-B49B-6D1C0C1057A7Q48323207-72D6916D-556D-46FD-BFF9-12EBE84F4C93Q51311518-91217940-E2BD-40E1-92A7-EB267C42285FQ57287866-016EC1E4-FA1C-440A-A250-C94EA012A09BQ58800521-B09693CF-6F66-4E58-89EB-A20B2B992ACC
P2860
Bortezomib inhibits expression of TGF-β1, IL-10, and CXCR4, resulting in decreased survival and migration of cutaneous T cell lymphoma cells.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Bortezomib inhibits expression ...... taneous T cell lymphoma cells.
@en
type
label
Bortezomib inhibits expression ...... taneous T cell lymphoma cells.
@en
prefLabel
Bortezomib inhibits expression ...... taneous T cell lymphoma cells.
@en
P2093
P2860
P356
P1476
Bortezomib inhibits expression ...... taneous T cell lymphoma cells.
@en
P2093
Ivana Vancurova
Tzu-Pei Chang
Vladimir Poltoratsky
P2860
P304
P356
10.4049/JIMMUNOL.1402610
P407
P577
2015-02-13T00:00:00Z